Ravulizumab for acute exacerbations in neuromyelitis optica spectrum disorder: A report of three cases

Masahiro Mori; Akiyuki Uzawa; Takahiro Makino; Yutaka Watabe; Hiroki Masuda; Tomoki Machino; Shinji Aoyama

doi:10.1016/j.jns.2025.124552

December 1, 2025Journal of the Neurological Sciences

Ravulizumab for acute exacerbations in neuromyelitis optica spectrum disorder: A report of three cases

View at Publisher

Ask AI

Bookmark

Share

Key Points

Ravulizumab effectively reduces acute exacerbations in neuromyelitis optica spectrum disorder, improving symptoms.
In three cases, patients showed significant recovery following ravulizumab treatment, with improved clinical measures.
Observational assessment of three cases illustrated clinical decisions on immunotherapy approaches for treatment options.
Highlights the need for further studies to confirm findings in larger, diverse patient populations.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis describes ravulizumab aiding recovery from acute exacerbations in neuromyelitis optica, highlighting potential benefits of immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mori et al. (2025) studied this question.

synapsesocial.com/papers/69a75ee8c6e9836116a29ee0 https://doi.org/10.1016/j.jns.2025.124552

View at Publisher

Ask AI

Bookmark

Share

Ravulizumab for acute exacerbations in neuromyelitis optica spectrum disorder: A report of three cases

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Ravulizumab for acute exacerbations in neuromyelitis optica spectrum disorder: A report of three cases

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading